Neurocrine reports Q2 2026 results, raises INGREZZA guidance, cites 2027 pipeline readouts

Neurocrine Biosciences said its late-stage pipeline remains on track, with CEO Kyle Gano noting multiple important clinical milestones expected in 2027, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia.¹

The company also disclosed new two-year data updates from its CAHtalyst program. In the pediatric study, Neurocrine reported positive growth outcomes in children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY over two years.¹ In the adult study, the company reported improved cardiometabolic outcomes alongside sustained glucocorticoid dose reduction in patients treated with CRENESSITY for up to two years.¹ Neurocrine separately said it published expert recommendations on glucocorticoid dose reduction after starting CRENESSITY treatment.¹

On VYKAT XR, acquired through the Soleno Therapeutics deal that closed in May 2026, the company presented new data showing meaningful and durable improvements in hyperphagia and behavioral symptoms in Prader-Willi syndrome following a randomized withdrawal period.¹ The company also initiated a Phase 2 study of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia.¹

On regulatory and corporate fronts, Neurocrine completed its acquisition of Soleno Therapeutics for $53.00 per share in cash, a transaction valued at $2.9 billion.¹ It also entered a $1.0 billion senior secured revolving credit facility in May 2026, with the full $1.0 billion in borrowing capacity still available as of June 30, 2026.¹

Cash position: the company held approximately $482 million in cash, cash equivalents, and marketable securities at June 30, 2026.¹ Neurocrine raised its full-year 2026 INGREZZA guidance, increasing the range from $2.7 billion to $2.8 billion up to $2.825 billion to $2.875 billion.¹